Dasher Neuroscience Completes Patient Enrollment for Global Phase 2 Study of YA-101 for MSA Treatment
Dasher Neuroscience Holdings Inc. (TPEx: 7829), a leading AI-powered biopharmaceutical firm focused on drugs for Central Nervous System (CNS) disorders, has reached a significant milestone by successfully completing the patient recruitment for its worldwide Phase 2 clinical trial of YA-101, its lead drug candidate targeting multiple system atrophy (MSA).
This study is pivotal as it aims to provide crucial clinical data on both the safety and efficacy of YA-101, with top-line results expected to be disclosed in the first quarter of 2027. Dr. Jane Tseng, CEO of Dasher Neuroscience, emphasized the importance of this recruitment milestone, which lays a strong groundwork for engaging potential global licensing partners while working towards making this innovative therapy available to patients suffering from rare diseases.
The study design is a global, multicenter, double-blind, placebo-controlled dose escalation trial involving 90 patients across clinical sites in the United States, Japan, and Taiwan. Participants of this trial are diagnosed with MSA according to criteria set by the Movement Disorder Society (MDS). Both subtypes of MSA, Parkinsonian (MSA-P) and cerebellar (MSA-C), are being evaluated in this research.
Key endpoints in the study include measuring the frequency and severity of adverse events to assess the safety and tolerability of YA-101. Secondary endpoints will examine pharmacokinetic parameters and clinical efficacy assessed through the Unified Multiple System Atrophy Rating Scale (UMSARS) and the 10-Meter Walk Test.
YA-101 is classified as a New Chemical Entity (NCE) and functions as a D-amino acid oxidase inhibitor (DAOI). This mechanism targets inflammatory cytokines primarily by reducing neuroinflammation and enhancing neuroplasticity, aimed at improving the disease trajectory in MSA patients. Importantly, YA-101 has received Fast-Track designation from the U.S. FDA and orphan drug designation from regulatory authorities in the US, Japan, and the EU.
MSA is a rare and rapidly progressive neurodegenerative disorder typically manifesting around the age of 50. Tragically, up to 80% of patients become severely disabled within five years of diagnosis, with median survival rates ranging from six to ten years. Current therapeutic approaches are limited to symptomatic relief, and no disease-modifying agents are currently approved — a pressing medical need worldwide.
The estimated global prevalence of MSA stands at approximately 5 cases per 100,000 people, with between 15,000 and 50,000 individuals in the U.S., 18,000 to 70,000 in the EU, 12,000 in Japan, and 2,000 in Taiwan affected by this devastating condition. Upon gaining regulatory approval, YA-101 aims to bridge this substantial treatment gap and offer new therapeutic hope to patients around the globe.
Dasher Neuroscience, listed on the Taiwan Emerging Stock Board since June 3, 2025, is set on utilizing AI to expedite therapies aimed at CNS disorders. In addition to YA-101, which is currently in Phase 2 clinical trials, the company is also developing YA-102 for Parkinson's disease and two preclinical candidates: YA-201 for Alzheimer's disease and YA-301 for schizophrenia. With a commitment to addressing unmet medical needs, Dasher strives to deliver innovative, safe, and effective treatment options.
This study is pivotal as it aims to provide crucial clinical data on both the safety and efficacy of YA-101, with top-line results expected to be disclosed in the first quarter of 2027. Dr. Jane Tseng, CEO of Dasher Neuroscience, emphasized the importance of this recruitment milestone, which lays a strong groundwork for engaging potential global licensing partners while working towards making this innovative therapy available to patients suffering from rare diseases.
The study design is a global, multicenter, double-blind, placebo-controlled dose escalation trial involving 90 patients across clinical sites in the United States, Japan, and Taiwan. Participants of this trial are diagnosed with MSA according to criteria set by the Movement Disorder Society (MDS). Both subtypes of MSA, Parkinsonian (MSA-P) and cerebellar (MSA-C), are being evaluated in this research.
Key endpoints in the study include measuring the frequency and severity of adverse events to assess the safety and tolerability of YA-101. Secondary endpoints will examine pharmacokinetic parameters and clinical efficacy assessed through the Unified Multiple System Atrophy Rating Scale (UMSARS) and the 10-Meter Walk Test.
YA-101 is classified as a New Chemical Entity (NCE) and functions as a D-amino acid oxidase inhibitor (DAOI). This mechanism targets inflammatory cytokines primarily by reducing neuroinflammation and enhancing neuroplasticity, aimed at improving the disease trajectory in MSA patients. Importantly, YA-101 has received Fast-Track designation from the U.S. FDA and orphan drug designation from regulatory authorities in the US, Japan, and the EU.
MSA is a rare and rapidly progressive neurodegenerative disorder typically manifesting around the age of 50. Tragically, up to 80% of patients become severely disabled within five years of diagnosis, with median survival rates ranging from six to ten years. Current therapeutic approaches are limited to symptomatic relief, and no disease-modifying agents are currently approved — a pressing medical need worldwide.
The estimated global prevalence of MSA stands at approximately 5 cases per 100,000 people, with between 15,000 and 50,000 individuals in the U.S., 18,000 to 70,000 in the EU, 12,000 in Japan, and 2,000 in Taiwan affected by this devastating condition. Upon gaining regulatory approval, YA-101 aims to bridge this substantial treatment gap and offer new therapeutic hope to patients around the globe.
Dasher Neuroscience, listed on the Taiwan Emerging Stock Board since June 3, 2025, is set on utilizing AI to expedite therapies aimed at CNS disorders. In addition to YA-101, which is currently in Phase 2 clinical trials, the company is also developing YA-102 for Parkinson's disease and two preclinical candidates: YA-201 for Alzheimer's disease and YA-301 for schizophrenia. With a commitment to addressing unmet medical needs, Dasher strives to deliver innovative, safe, and effective treatment options.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.